ASH 2020 | Advances of antibody therapy in ALL
David Marks
• 4 Dec 2020
David Marks, MB, MS, FRACP, PhD, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, discusses the recent advances in antibody therapy in acute lymphoblastic leukemia (ALL). Exciting developments have come from the novel antibodies blinatumomab and inotuzumab, as well as the development of CAR T-cell therapy. Additionally, inotuzumab and blinatumomab are both major advances in relapsed/refractory ALL. Antibody chemotherapy combinations also offer significant clinical benefit for older patients with Philadelphia positive ALL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
